TY - JOUR
T1 - Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer
AU - Gainor, Justin F.
AU - Tseng, Diane
AU - Yoda, Satoshi
AU - Dagogo-Jack, Ibiayi
AU - Friboulet, Luc
AU - Lin, Jessica J.
AU - Hubbeling, Harper G.
AU - Dardaei, Leila
AU - Farago, Anna F.
AU - Schultz, Katherine R.
AU - Ferris, Lorin A.
AU - Piotrowska, Zofia
AU - Hardwick, James
AU - Huang, Donghui
AU - Mino-Kenudson, Mari
AU - John Iafrate, A.
AU - Hata, Aaron N.
AU - Yeap, Beow Y.
AU - Shaw, Alice T.
N1 - Publisher Copyright:
© 2017 by American Society of Clinical Oncology
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Purpose The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1% to 2% of non-small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with the anaplastic lymphoma kinase (ALK)/ROS1/mesenchymal-epithelial transition factor inhibitor crizotinib. Currently, insights into patterns of metastatic spread and mechanisms of crizotinib resistance among patients with ROS1-positive disease are limited. Patients and Methods We reviewed clinical and radiographic imaging data of patients with ROS1- and ALK-positive NSCLC to compare patterns of metastatic spread at initial metastatic diagnosis. To determine molecular mechanisms of crizotinib resistance, we analyzed repeat biopsy specimens from a cohort of patients with ROS1-positive disease who progressed on crizotinib. Results We identified 39 and 196 patients with advanced ROS1- and ALK-positive NSCLC, respectively. Patients with ROS1-positive disease had significantly lower rates of extrathoracic metastases (ROS1, 59.0%; ALK, 83.2%; P =.002), including lower rates of brain metastases (ROS1, 19.4%; ALK, 39.1%; P =.033), at initial metastatic diagnosis. Despite similar overall survival between patients with ALK- and ROS1-positive NSCLC treated with crizotinib (median, 3.0 v 2.5 years, respectively; P =.786), patients with ROS1-positive NSCLC also had a significantly lower cumulative incidence of brain metastases (34% v 73% at 5 years; P <.001). In addition, we identified 16 patients who underwent a total of 17 repeat biopsies after progression on crizotinib. ROS1 resistance mutations were identified in 53% of specimens, including nine (64%) of 14 non-brain metastasis specimens. ROS1 mutations included G2032R (41%), D2033N (6%), and S1986F (6%). Conclusion Compared with ALK rearrangements, ROS1 rearrangements are associated with lower rates of extrathoracic metastases, including fewer brain metastases, at initial metastatic diagnosis. ROS1 resistance mutations, particularly G2032R, appear to be the predominant mechanism of resistance to crizotinib, which underscores the need to develop novel ROS1 inhibitors with activity against these resistant mutants.
AB - Purpose The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1% to 2% of non-small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with the anaplastic lymphoma kinase (ALK)/ROS1/mesenchymal-epithelial transition factor inhibitor crizotinib. Currently, insights into patterns of metastatic spread and mechanisms of crizotinib resistance among patients with ROS1-positive disease are limited. Patients and Methods We reviewed clinical and radiographic imaging data of patients with ROS1- and ALK-positive NSCLC to compare patterns of metastatic spread at initial metastatic diagnosis. To determine molecular mechanisms of crizotinib resistance, we analyzed repeat biopsy specimens from a cohort of patients with ROS1-positive disease who progressed on crizotinib. Results We identified 39 and 196 patients with advanced ROS1- and ALK-positive NSCLC, respectively. Patients with ROS1-positive disease had significantly lower rates of extrathoracic metastases (ROS1, 59.0%; ALK, 83.2%; P =.002), including lower rates of brain metastases (ROS1, 19.4%; ALK, 39.1%; P =.033), at initial metastatic diagnosis. Despite similar overall survival between patients with ALK- and ROS1-positive NSCLC treated with crizotinib (median, 3.0 v 2.5 years, respectively; P =.786), patients with ROS1-positive NSCLC also had a significantly lower cumulative incidence of brain metastases (34% v 73% at 5 years; P <.001). In addition, we identified 16 patients who underwent a total of 17 repeat biopsies after progression on crizotinib. ROS1 resistance mutations were identified in 53% of specimens, including nine (64%) of 14 non-brain metastasis specimens. ROS1 mutations included G2032R (41%), D2033N (6%), and S1986F (6%). Conclusion Compared with ALK rearrangements, ROS1 rearrangements are associated with lower rates of extrathoracic metastases, including fewer brain metastases, at initial metastatic diagnosis. ROS1 resistance mutations, particularly G2032R, appear to be the predominant mechanism of resistance to crizotinib, which underscores the need to develop novel ROS1 inhibitors with activity against these resistant mutants.
UR - http://www.scopus.com/inward/record.url?scp=85086159330&partnerID=8YFLogxK
U2 - 10.1200/PO.17.00063
DO - 10.1200/PO.17.00063
M3 - Article
AN - SCOPUS:85086159330
SN - 2473-4284
VL - 1
JO - JCO Precision Oncology
JF - JCO Precision Oncology
ER -